Regeneron Pharmaceuticals, Inc. (REGN) Cash Flow Statement

The wide fluctuation in OCF/NI, from 0.25 to 2.09, points to large working capital swings rather than stable earnings quality. In 2026Q2, net income of $1.3B far exceeded operating cash flow of $574.5M, with working capital changes consuming $161.1M, suggesting that reported earnings may not be fully converting to cash in the near term. Investors should monitor whether this pattern persists, as it may indicate aggressive revenue recognition or inventory build-up.

The FCF margin contraction from 42.9% to 7.8% over the period reflects both lower operating cash flow and higher capital expenditures. While 2025Q3 showed a robust 37.8% margin, the most recent quarter's weakness suggests that growth investments and competitive pressures are weighing on cash generation. This trend aligns with the income statement's decelerating revenue growth, implying that FCF may remain under pressure if Eylea competition intensifies.

The capex-to-revenue ratio has trended upward, with 2025Q2's 11.1% nearly double the 2024 average, indicating a shift toward growth-oriented spending. This elevated capital intensity may reflect expansion for new product launches or biosimilar defenses, but it also pressures near-term FCF. Given the company's high R&D spending, investors should assess whether these investments will generate sufficient returns to offset the rising depreciation burden.

The extreme fluctuations in working capital, particularly the $908.5M outflow in 2024Q2 and the $625.0M inflow in 2025Q3, suggest that cash flow timing is heavily influenced by receivables and inventory management. This volatility complicates the assessment of underlying cash generation, as it may mask true operational performance. Investors should focus on normalized working capital trends over multiple quarters to gauge efficiency.

The company has deployed substantial cash toward share repurchases, with quarterly buybacks ranging from $291.3M to $1.2B, far exceeding dividend payments. This capital deployment strategy suggests management's confidence in the stock's value, but it also reduces cash reserves that could be used for pipeline investments or acquisitions. Given the competitive threats to Eylea, investors should monitor whether this aggressive buyback pace is sustainable without compromising future growth opportunities.

The cumulative gap between net income and operating cash flow is relatively small, indicating that overall earnings quality is reasonable. However, the quarterly volatility in OCF/NI, including a low of 0.25, suggests that timing differences can be significant. This divergence may reflect the impact of working capital changes and non-cash items, but it does not appear to signal a systemic problem. Investors should continue to monitor the trend to ensure it does not widen.